Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma. When initially reported with a median follow-up of 42 months, complete response rate and event-free survival were superior among the 323 pat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Barlogie, Bart, Pineda-Roman, Mauricio, van Rhee, Frits, Haessler, Jeff, Anaissie, Elias, Hollmig, Klaus, Alsayed, Yazan, Waheed, Sarah, Petty, Nathan, Epstein, Joshua, Shaughnessy, John D., Tricot, Guido, Zangari, Maurizio, Zeldis, Jerome, Barer, Sol, Crowley, John
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2008
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2569166/
https://ncbi.nlm.nih.gov/pubmed/18492953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-03-145235
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki